Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Endocrinology · Primary Aldosteronism

Why Does eGFR Decline After Primary Aldosteronism Treatment?

At a Glance

After primary aldosteronism is treated, eGFR often falls because excessive kidney filtration pressure returns to normal, revealing a more accurate baseline. A modest early decline may be expected, but a sudden, large, or ongoing drop needs medical evaluation.

A modest early decline in your estimated glomerular filtration rate (eGFR) is common after starting treatment for primary aldosteronism [1]. While it can be frightening to see a lower number on your lab report, this drop is often an anticipated change as your kidneys adjust to a normal hormone environment [2].

However, a drop in eGFR is not automatically harmless. A sudden, large, or continuing decline requires medical evaluation to rule out acute kidney injury, dehydration, or medication side effects [3].

When to Call Your Care Team

Contact your doctor promptly if you experience any of the following symptoms, and do not stop or change your treatment without clinician guidance:

  • Fainting, severe dizziness, or very low blood pressure
  • Markedly reduced urine output
  • Inability to keep fluids down (such as severe vomiting or diarrhea)
  • Severe weakness or palpitations (which can be signs of a potassium imbalance)

The “Unmasking” Effect

To understand why your eGFR might drop safely, it helps to know how excess aldosterone affects the body. Primary aldosteronism causes the kidneys to filter blood at an unusually high pressure—a state called hyperfiltration [2].

Treatments are designed to remove this excess hormone and relieve the pressure on your kidneys. This is typically done through surgery (adrenalectomy, usually for disease in just one adrenal gland) or medications called mineralocorticoid-receptor antagonists (MRAs like spironolactone or eplerenone, used when both glands are overactive or surgery is not pursued) [2].

When the high filtration pressure normalizes, your measured eGFR naturally falls to establish a new, post-treatment baseline [1]. Doctors call this the “unmasking” effect. The drop does not necessarily mean the treatment caused new kidney damage; rather, it often reveals preexisting kidney wear-and-tear that was previously hidden by the hyperfiltration [4][5]. This prior damage is often the result of prolonged high blood pressure and the direct vascular effects of primary aldosteronism [4].

In a combined analysis of patients after treatment (both surgery and medication), the average eGFR decrease was roughly 10.7 points (mL/min/1.73 m²) after about a year [1]. However, this is a group average, not a target or a prediction for every individual.

How Doctors Evaluate Your True Kidney Function

Because eGFR is an estimate that can fluctuate based on hydration, blood pressure, and medications, a single low reading does not automatically mean you have permanent chronic kidney disease (CKD). A CKD diagnosis generally requires an eGFR below 60 or signs of kidney damage persisting for at least three months, interpreted alongside your past lab results [6].

To get a full picture of your kidney health, your doctor will look at multiple factors. One common check is measuring the amount of protein leaking into your urine (albuminuria). Research shows that while eGFR may fall after treatment, albuminuria often improves once the hyperfiltration is stopped [7][1]. (Some specialized research studies also show that biological markers of kidney stress, like L-FABP and KIM-1, decrease after treatment, further supporting that the eGFR dip often represents a healthy relief of pressure [7]).

Long-Term Monitoring and Medication Safety

For many patients, the decline in eGFR happens early in treatment and then stabilizes into a new baseline [8][9]. Ongoing monitoring is essential to ensure it stays stable.

  • Follow a monitoring timeline: Your clinician will commonly check your creatinine/eGFR, potassium, and blood pressure soon after starting treatment, after any medication dose changes, and at individualized intervals long-term [10].
  • Medication adjustments: If you take an MRA, your doctor will individualize your dose based on a combination of your blood pressure, potassium, eGFR, symptoms, and sometimes renin levels [11]. Never adjust this medication on your own.
  • Be cautious with potassium and other meds: MRAs help your body hold onto potassium. Always ask your doctor before using potassium supplements, salt substitutes (which contain potassium), or over-the-counter painkillers like NSAIDs (ibuprofen, naproxen), which can alter kidney function and dangerously increase potassium levels [10].

Common questions in this guide

Is a drop in eGFR after primary aldosteronism treatment normal?
A modest early drop is common because treatment relieves unusually high-pressure filtration in the kidneys. The new number may reflect a more accurate baseline rather than new kidney damage, but your clinician should interpret the trend and other test results.
Why can eGFR fall after adrenalectomy or spironolactone?
Surgery and medicines such as spironolactone or eplerenone reduce the effects of excess aldosterone. As abnormal kidney filtration pressure returns toward normal, the measured eGFR often falls; this is sometimes called an unmasking effect and does not automatically mean permanent kidney injury.
How much eGFR decline is expected after treatment?
In one combined group of treated patients, the average decline was about 10.7 mL/min/1.73 m² after roughly one year. This is a group average, not a target or a prediction of what will happen to one person.
When is a lower eGFR after treatment concerning?
A sudden, large, or continuing decline needs medical evaluation because it can be related to acute kidney injury, dehydration, low blood pressure, or a medication effect. Seek prompt help for fainting, severe dizziness, very little urine, inability to keep fluids down, severe weakness, or palpitations.
How do doctors tell whether my kidney function is truly worsening?
They compare repeated eGFR and creatinine results with your prior tests and review hydration, blood pressure, medicines, and urine albumin. Chronic kidney disease generally requires an eGFR below 60 or signs of kidney damage that persist for at least three months.
What should I avoid while taking spironolactone or eplerenone?
Ask your clinician before using potassium supplements, salt substitutes containing potassium, or NSAID pain relievers such as ibuprofen or naproxen. These products can affect kidney function and may raise potassium to unsafe levels when combined with these medicines.
How often should kidney tests be checked after treatment?
Clinicians commonly check creatinine or eGFR, potassium, and blood pressure soon after treatment begins and after medication doses change. Longer-term testing is individualized based on your results, symptoms, and treatment plan.

Get notified when new evidence is published on hyperaldosteronism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Renal damage in primary aldosteronism: a systematic review and meta-analysis.

    Monticone S, Sconfienza E, D'Ascenzo F, et al.

    Journal of hypertension 2020; (38(1)):3-12 doi:10.1097/HJH.0000000000002216.

    PMID: 31385870
  2. 2

    Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism.

    Kobayashi Y, Haze T, Yano Y, et al.

    Kidney international reports 2020; (5(8)):1291-1297 doi:10.1016/j.ekir.2020.06.012.

    PMID: 32775828
  3. 3

    Association of Dip in eGFR With Clinical Outcomes in Unilateral Primary Aldosteronism Patients After Adrenalectomy.

    Chen JY, Huang KH, Lin YH, et al.

    The Journal of clinical endocrinology and metabolism 2024; (109(3)):e965-e974 doi:10.1210/clinem/dgad709.

    PMID: 38051943
  4. 4

    Unmasked chronic renal function deterioration after unilateral adrenalectomy in patients with primary aldosteronism.

    Park SM, Jung WJ, Park JM, et al.

    Kidney research and clinical practice 2016; (35(4)):255-258 doi:10.1016/j.krcp.2016.05.002.

    PMID: 27957422
  5. 5

    Effects of Treating Primary Aldosteronism on Renal Function.

    Kramers BJ, Kramers C, Lenders JW, Deinum J

    Journal of clinical hypertension (Greenwich, Conn.) 2017; (19(3)):290-295 doi:10.1111/jch.12914.

    PMID: 27659389
  6. 6

    Is acute kidney injury after laparoscopic adrenalectomy related to the progression of chronic kidney disease in patients with primary aldosteronism?

    Yoon JH, Chung HS, Hong AR, et al.

    Investigative and clinical urology 2021; (62(5)):560-568 doi:10.4111/icu.20200582.

    PMID: 34387032
  7. 7

    Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.

    Wu VC, Chan CK, Chueh JS, et al.

    Journal of the American Heart Association 2023; (12(4)):e028146 doi:10.1161/JAHA.122.028146.

    PMID: 36789834
  8. 8

    Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.

    Nakano Y, Murakami M, Hara K, et al.

    Clinical endocrinology 2023; (98(3)):323-331 doi:10.1111/cen.14849.

    PMID: 36367014
  9. 9

    Renal Function Evolution and Hypoaldosteronism Risk After Unilateral Adrenalectomy for Primary Aldosteronism.

    Queiroz NL, Stumpf MAM, Souza VCM, et al.

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2024; (56(5)):350-357 doi:10.1055/a-2221-3302.

    PMID: 38040032
  10. 10

    Persistent severe hyperkalemia following surgical treatment of aldosterone-producing adenoma.

    Preda C, Teodoriu LC, Placinta S, et al.

    Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2020; (25()):17 doi:10.4103/jrms.JRMS_603_19.

    PMID: 32174989
  11. 11

    Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.

    Katsuragawa S, Goto A, Shinoda S, et al.

    Hypertension (Dallas, Tex. : 1979) 2023; (80(9)):1909-1920 doi:10.1161/HYPERTENSIONAHA.123.21096.

    PMID: 37449450

This page is for informational purposes only and does not replace professional medical advice. Discuss changes in eGFR, potassium, blood pressure, or medicines with your clinician, and do not change treatment on your own.